EXAS - Exact Sciences Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
79.71
+3.64 (+4.79%)
At close: 4:00PM EST

79.71 0.00 (0.00%)
After hours: 6:18PM EST

Stock chart is not supported by your current browser
Previous Close76.07
Open76.34
Bid78.78 x 1000
Ask79.71 x 800
Day's Range76.29 - 81.00
52 Week Range37.36 - 82.85
Volume2,470,620
Avg. Volume1,818,137
Market Cap9.796B
Beta (3Y Monthly)3.02
PE Ratio (TTM)N/A
EPS (TTM)-1.18
Earnings DateFeb 20, 2019 - Feb 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est89.73
Trade prices are not sourced from all markets
  • Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
    Zacks14 hours ago

    Is a Beat in Store for AbbVie (ABBV) This Earnings Season?

    AbbVie (ABBV) is likely to beat earnings in fourth quarter. Impressive sales of its key drug, Humira and strong growth of Imbruvica and Mavyret are expected to drive fourth-quarter sales.

  • Exact Sciences (EXAS) Is Up 16.34% in One Week: What You Should Know
    Zacks7 days ago

    Exact Sciences (EXAS) Is Up 16.34% in One Week: What You Should Know

    Does Exact Sciences (EXAS) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • 3 Healthcare Stocks Still Raising Expectations
    Motley Fool9 days ago

    3 Healthcare Stocks Still Raising Expectations

    If you're worried about recent guidance revisions downward, here are three top stocks from the healthcare sector that recently raised their outlook.

  • What Caused Exact Sciences Shares to Fall 19.1% in December
    Motley Fool9 days ago

    What Caused Exact Sciences Shares to Fall 19.1% in December

    Shares of the molecular diagnostics company reverted to the mean last month, perhaps creating a tremendous buying opportunity for aggressive investors.

  • Barrons.com16 days ago

    Exact Sciences Stock Soars as Upbeat Forecast Raises Hopes

    Exact Sciences’ best-known diagnostic test has achieved increasing sales, and one analyst sees more growth to come.

  • Why Exact Sciences Soared Today
    Motley Fool16 days ago

    Why Exact Sciences Soared Today

    The molecular-diagnostics company's early look at Q4 and full-year 2018 revenue numbers revved up investors.

  • Three Healthcare Stocks Rallying Over 10% Today
    Market Realist16 days ago

    Three Healthcare Stocks Rallying Over 10% Today

    Three Healthcare Stocks Rallying Over 10% Today ## Three healthcare stocks The broader market is trading in the green territory today but largely on a mixed note compared to the volatility in the previous couple of sessions. At 11:40 AM ET, the S&P 500 Index (SPY), NASDAQ Composite Index (QQQ), and Dow Jones Industrial Average were trading with 0.8%, 1.1%, and 0.6% gains. However, some healthcare stocks (XLV)(VHT)(IBB) were making huge moves today. Let’s take a look. ## Loxo Oncology Today before the market opened, the American pharmaceutical giant Eli Lilly and Company (LLY) announced the acquisition of Loxo Oncology (LOXO). According to the agreement between the two companies, Eli Lilly will acquire Loxo for $235.00 per share in cash, which translates into approximately $8.0 billion. After the news came out, Loxo stock surged nearly 66.0% to $232.12. ## Sage Therapeutics The biopharmaceutical firm Sage Therapeutics (SAGE) revealed positive results of the Phase 3 ROBIN Study today. The outcome of the study suggested a “significant improvement” in women with postpartum depression (or PPD) who were treated with its SAGE-217 drug for two weeks. This news boosted investors’ confidence, and SAGE stock surged 62.1% to a day high of $158.09. ## Exact Sciences The molecular diagnostics firm Exact Sciences (EXAS) said today that it expects its fourth quarter of 2018 revenue between $142.5 million and $143.5 million, which reflected about a 64% rise in its revenue from the fourth quarter of the previous year. In a press release, the company said that it “completed approximately 292,000 Cologuard tests during the fourth quarter of 2018,” up about 66% year-over-year. Plus, Exact Sciences noted, “Nearly 15,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2018.” These positive developments drove EXAS stock to rally today to post a day high of $72.78, up 11.0% from its previous session’s closing price. Note that in 2018, LOXO, LLY, and EXAS rose 66.4%, 37.0%, and 20.1%, respectively, while SAGE fell 41.8%.

  • Why Exact Sciences Surged 12% Today
    Market Realist17 days ago

    Why Exact Sciences Surged 12% Today

    Why Exact Sciences Surged 12% Today ## Price movement On January 7, Exact Sciences (EXAS) rose 11.96% as compared to its previous closing price and reached $73.50 in the pre-market trading session on NASDAQ. This movement followed the company’s press release announcing preliminary revenue results for the fourth quarter of 2018 and fiscal 2018. According to the press release, Exact Sciences expects to report revenues in the range of $142.5 million and $143.5 million for the fourth quarter of 2018, a YoY rise of 64%. The company also expects to report revenues in the range of $454 million and $455 million for fiscal 2018, a YoY rise of 71%. This performance has been driven by the robust rise in demand for the Cologuard test indicated for screening adults for colorectal cancer. According to the press release, Exact Sciences reported total Cologuard volumes of 934,000 tests, a YoY rise of 64%. Based on its closing price on January 4, the company reported returns of 8.15% in the last week, -20.58% in the last month, and -14.55% in the last quarter. Exact Sciences also reported returns of 5.51% in the last half year, 17.59% in the last year, and 4.04% YTD. ## Analyst recommendations and target price for Exact Sciences The 12-month consensus analyst recommendation for Exact Sciences on January 7 is a “buy.” The 12-month consensus target price for the company is $88, which is 21.38% higher than its last closing price on January 4. The highest target price estimate for the company is $100 and the lowest target price estimate is $75. Out of the 13 analysts covering Exact Sciences on January 7, seven analysts have rated the company as a “strong buy,” three analysts have rated the company as a “buy,” and three analysts have rated the company as a “hold.”

  • Barrons.com17 days ago

    Exact Sciences Stock Soars, General Motors Gains and 5 More Monday Morning Movers

    STOCKSTOWATCHTODAY BLOG Dow Jones Industrial Average futures were trading up slightly Monday morning after trading lower earlier as trade talks between the U.S. and China begin. Here are seven stocks making moves Monday morning: (EXAS) (EXAS) is up 10.

  • ACCESSWIRE17 days ago

    Today's Research Reports on Trending Tickers: Exact Sciences and Illumina

    NEW YORK, NY / ACCESSWIRE / January 7, 2019 / U.S. markets surged on Friday as employment data came in well above expectations. The Bureau of Labor Statistics reported 312,000 jobs were added in December, ...

  • Does Exact Sciences Corporation’s (NASDAQ:EXAS) CEO Pay Matter?
    Simply Wall St.29 days ago

    Does Exact Sciences Corporation’s (NASDAQ:EXAS) CEO Pay Matter?

    Kevin Conroy has been the CEO of Exact Sciences Corporation (NASDAQ:EXAS) since 2009. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at Read More...

  • Are Options Traders Betting on a Big Move in Exact Sciences (EXAS) Stock?
    Zackslast month

    Are Options Traders Betting on a Big Move in Exact Sciences (EXAS) Stock?

    Investors need to pay close attention to Exact Sciences (EXAS) stock based on the movements in the options market lately.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Neogen and Exact Sciences

    NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...

  • These 3 Stocks Are Up 25% in 2018 -- Are They Still Buys?
    Motley Fool2 months ago

    These 3 Stocks Are Up 25% in 2018 -- Are They Still Buys?

    Despite the recent sell-offs, some stocks are still up big this year. Here are three that deserve a closer look.

  • Better Buy: EXACT Sciences Corporation vs. Illumina
    Motley Fool2 months ago

    Better Buy: EXACT Sciences Corporation vs. Illumina

    Which of these two fast growers in the smarter choice for new money today?

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: OPKO Health and Exact Sciences

    NEW YORK, NY / ACCESSWIRE / November 13, 2018 / OPKO Health was seeing big gains in Monday’s session on a stellar third quarter report. Shares of Exact Sciences Corp. were plummeting despite any remarkable ...

  • Is Exact Sciences Corporation a Buy?
    Motley Fool3 months ago

    Is Exact Sciences Corporation a Buy?

    It's riding high right now. But can Exact Sciences keep the momentum going?

  • GlobeNewswire3 months ago

    Report: Exploring Fundamental Drivers Behind MRC Global, Exact Sciences, Owens-Illinois, Copart, Cognizant Technology Solutions, and Owens & Minor — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 05, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Here's What Exact Sciences Just Said About Its Future
    Motley Fool3 months ago

    Here's What Exact Sciences Just Said About Its Future

    Sales are surging, but the company is only scratching the surface of its addressable market.

  • Why Accuray Is Soaring Today
    Motley Fool3 months ago

    Why Accuray Is Soaring Today

    Shares jump after the company reports mixed fiscal 2019 first-quarter results.

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: Exact Sciences and Illumina

    NEW YORK, NY / ACCESSWIRE / October 31, 2018 / U.S. markets rebounded on Tuesday as trade tensions eased after President Trump hinted that the U.S. was prepared to negotiate a trade deal with China. During ...

  • Exact Sciences (EXAS) Reports Q3 Loss, Tops Revenue Estimates
    Zacks3 months ago

    Exact Sciences (EXAS) Reports Q3 Loss, Tops Revenue Estimates

    Exact Sciences (EXAS) delivered earnings and revenue surprises of 28.57% and 8.33%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Implied Volatility Surging for Exact Sciences (EXAS) Stock Options
    Zacks3 months ago

    Implied Volatility Surging for Exact Sciences (EXAS) Stock Options

    Investors need to pay close attention to Exact Sciences (EXAS) stock based on the movements in the options market lately.

  • Simply Wall St.3 months ago

    Does Exact Sciences Corporation’s (NASDAQ:EXAS) Debt Level Pose A Problem?

    Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Exact Sciences Corporation (NASDAQ:EXAS), with a market capitalization of US$8.3b, rarely draw their attention from the investing Read More...